Relapsed and refractory aggressive NHL: Time for a change

被引：15
|
作者：
Gangatharan, Shane [1 ]
Kuruvilla, John [1 ,2 ]
机构：
[1] Princess Margaret Canc Ctr, Div Med Oncol & Hematol, Toronto, ON M5G 2M9, Canada
[2] Univ Toronto, Dept Med, Toronto, ON, Canada
来源：
TRANSFUSION AND APHERESIS SCIENCE | 2013年 / 49卷 / 01期
关键词：
B-CELL LYMPHOMA; NON-HODGKINS-LYMPHOMA; PHASE-II TRIAL; HUMANIZED ANTI-CD22 ANTIBODY; PERIPHERAL T-CELL; AUTOLOGOUS TRANSPLANTATION; CONDITIONING REGIMENS; SALVAGE CHEMOTHERAPY; BRENTUXIMAB VEDOTIN; NONGERMINAL CENTER;
D O I：
10.1016/j.transci.2013.05.029
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Despite improvements in treatment for aggressive non-Hodgkin lymphoma (NHL), the outcomes for patients with relapsed or refractory B- or T-cell NHL after primary therapy remain poor. While some patients may be cured by the standard of care of salvage chemotherapy followed by high-dose chemotherapy and autologous stem cell transplantation (ASCT), this treatment is unsuitable for the majority. Advances in disease biology and novel therapies have created uncertainty as to the role of old standards and opportunities to develop new rationally developed treatment options. We will review the standard approaches in this disease area and highlight areas that merit further study. (C) 2013 Published by Elsevier Ltd.
引用
收藏
页码：72 / 79
页数：8
相关论文
共 50 条
  • [41] Population Pharmacokinetics of the Ofatumumab in Combination with Chemotherapy in Relapsed or Refractory Aggressive Lymphoma
    Singh, Rajendra P.
    Struemper, Herbert
    Patel, Bela R.
    Jewell, Roxanne C.
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2013, 40 : S113 - S113
  • [42] Strategies for introducing palliative care in the management of relapsed or refractory aggressive lymphomas
    Odejide, Oreofe O.
    HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2020, (01) : 148 - 153
  • [43] Treatment response to single agent sphingosomal vincristine in patients with relapsed and/or refractory diffuse aggressive non-Hodgkin's lymphoma (NHL): Subgroup analyses.
    Rodriguez, MA
    Winter, JN
    BLOOD, 2004, 104 (11) : 682A - 682A
  • [44] The GMALL-B-ALL/NHL protocol is an effective salvage treatment in relapsed and refractory aggressive B-cell non-Hodgkin's lymphomas
    Sakarou, M.
    Duehrsen, U.
    Huettmann, A.
    ONKOLOGIE, 2012, 35 : 40 - 40
  • [45] CR rates in relapsed/refractory (R/R) aggressive B-NHL treated with the CD19-directed CAR T-cell product JCAR017 (TRANSCEND NHL 001).
    Abramson, Jeremy S.
    Palomba, Maria Lia
    Gordon, Leo I.
    Lunning, Matthew Alexander
    Arnason, Jon E.
    Forero-Torres, Andres
    Wang, Michael
    Albertson, Tina M.
    Allen, Tara
    Sutherland, Claire
    Xie, Benhuai
    Garcia, Jacob
    Siddiqi, Tanya
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [46] Phase II study of oxaliplatin in patients with relapsed and refractory non-Hodgkin lymhoma (NHL)
    Younes, A
    McLaughlin, P
    Pro, B
    Hagemeister, F
    Bleyer, A
    BLOOD, 2003, 102 (11) : 639A - 640A
  • [47] 3-YEAR RESULTS OF MIM SALVAGE TREATMENT FOR REFRACTORY/RELAPSED INTERMEDIATE GRADE NHL
    ABATE, G
    TAFUTO, S
    MARCACCI, G
    CORAZZELLI, G
    FIMIANI, P
    MONDA, VM
    GAILLI, E
    DANDREA, P
    IACCARINO, G
    EUROPEAN JOURNAL OF HAEMATOLOGY, 1995, 54 (01) : 53 - 54
  • [48] BEAM-alemtuzumab followed by allogeneic SCT for the treatment of relapsed or refractory T-NHL
    Repp, R.
    Guenther, A.
    Schade, H.
    Humpe, A.
    Gahn, B.
    Nickelsen, M.
    Claviez, A.
    Schrauder, A.
    Gramatzki, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [49] Improved survival in aggressive NHL
    不详
    EUROPEAN JOURNAL OF CANCER, 2001, 37 (11) : 1326 - 1326
  • [50] PRESENCE OF SOLID TUMORS DOES NOT PREVENT AUTOLOGOUS STEM CELL TRANSPLANTATION IN REFRACTORY/RELAPSED NHL
    Arslan, Ismail
    Bilgin, Aynur Ugur
    Ilhan, Osman
    BONE MARROW TRANSPLANTATION, 2023, 58 (SUPP1) : 591 - 592
12345